

899 NORTH CAPITOL ST. NE – 2<sup>ND</sup> FLR.  
WASHINGTON, DC 20002

February 2, 2023

9:30 am

## OPEN SESSION AGENDA

**Board of Pharmacy Mission Statement:**

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”



## Open Session Agenda

Quorum:

Introduction:		
0202-O-01	<p><b><u>Approval of the Open Session Meeting Minutes for:</u></b></p> <p>December 1, 2022 January 5, 2023</p>	
<b><u>Consent Agenda</u></b>	None	
<b><u>Chairperson Report</u></b>	<b><u>Interprofessional Workgroup</u></b>	Dr. Tamara McCants
<b><u>Executive Director Report</u></b>	<ul style="list-style-type: none"> <li>▪ Statistical Report on Pharmacy professionals in the District of Columbia</li> <li>▪ Prescription Drug Monitoring Program Updates</li> <li>▪ DCRx (DC Center for Rational Prescribing)</li> <li>▪ Office of Government Relations (OGR) Updates</li> <li>▪ Pharmacist and Pharmacy Technician Renewals</li> </ul>	Dr. Justin Ortique
<b><u>Senior Assistant General Counsel Report</u></b>		
0202-O-02	<p><b><u>Notice of Final Rulemaking-Chapter 65 (Pharmacists) of Title 17 (Business, Occupations, and Professionals) of the District of Columbia Municipal Regulations (DCMR).</u></b></p> <p>(a) Notice of Final Rulemaking</p>	Ms. Carla Williams
<b><u>Regarding Subcommittee Reports</u></b>		
0202-O-03	<b><u>Legislative and Regulatory Subcommittee Report</u></b>	Mr. Alan Friedman
0202-O-04	<b><u>Communications Subcommittee Report</u></b>	Dr. Ashlee Bow
<b><u>Matter for Consideration</u></b>		
0202-O-05	<b><u>DC Board of Pharmacy Bylaws</u></b>	
0202-E-06	<p><b><u>Inquiry Regarding the Exemption for Pharmaceutical Detailers</u></b></p> <p>(a) Inquiry</p>	

<p><b><u>Presentation</u></b></p>	<p><b><u>Neal Watson, Senior Manager, Member Relations and Government Affairs at National Association of Boards of Pharmacy</u></b></p> <p>Introduction to a New Pharmacist Exam Eligibility Service</p> <p>(a) Presentation Slides (b) Pharmacist licensing fees</p>	
<p><b>NABP E-Newsletter</b></p>	<p><b><u>January 25, 2022</u></b></p> <p>FDA Issues Guidance for Compounding Ibuprofen Oral Suspension Products Under FD&amp;C Act</p> <p>DEA Addresses Suspicious Orders of CS With Guidance Document</p> <p>PQA Publishes Second Edition of the Social Determinants of Health Resource Guide</p> <p>DEA Outlines New Guidelines After Elimination of the DATA-Waiver Program</p> <p>Study Shows Flu Shot Decreased Outpatient Care Needed During the 2021-2022 Flu Season</p> <p>2023 Patient Safety Awareness Week Toolkit Available to Download for Free</p> <p><b><u>January 11, 2022</u></b></p> <p>MAT Act Signed Into Law, NABP Applauds Benefits for Overdose Prevention Recovery Support</p> <p>NCC MERP Offers Free Home Study Webinar, Pharmacist Tools to Support Patient Safety</p> <p>FDA Expands Rule Allowing Retail Pharmacists to Sell Abortion Medications</p> <p>NSDUH Results Show 61.2 Million People Used Illicit Drugs in 2021, According to SAMHSA and HHS</p> <p>Note to the Public: To receive weekly updates from NABP, please sign up by using the following link: <a href="https://nabp.pharmacy/newsroom/news/">https://nabp.pharmacy/newsroom/news/</a>.</p>	<p>Dr. Tamara McCants</p>
<p><b><u>Comments from the Public</u></b></p>		

<p><b><u>Motion to Adjourn the Open Session</u></b></p>	<p>“Madam Board Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14).” ROLL CALL VOTE</p>	
---	---	--

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

**Open Session Meeting Adjourned at \_\_:\_\_ AM.**

**This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at [opengovoffice@dc.gov](mailto:opengovoffice@dc.gov).**